Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
Sign Up to like & getrecommendations! Published in 2018 at "Cephalalgia"
DOI: 10.1177/0333102417747230
Abstract: Background Safety findings from a Phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (NCT02163993) are reported here. Methods Patients aged 18–65 years with episodic migraine were… read more here.
Keywords: phase; galcanezumab; treatment; study ... See more keywords